In addition to SGLT2 inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, and Glucagon-Like Peptide-1 (GLP-1) receptor agonists have shown significant efficacy for T2D management. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.